A Phase 2 interventional study of Elafibranor 80 mg and Elafibranor 120 mg in Primary Biliary Cholangitis (PBC), sponsored by Genfit. Completed at 24 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Genfit · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 34th largest by enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2017, is one of 34 in phase 2, and was the 36th registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
Ipsen · Sites in United States
Women only
Zydus Therapeutics Inc. · Sites in United States
Ages 18+
Zydus Therapeutics Inc. · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 38 · Phase 3 18 · Phase 4 3
First in 1994; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 46 across the 65 interventional studies, 430 across the 17 observational. Of the 61 that completed or were terminated, 33 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 83 have an industry lead sponsor. The 10 most frequent:
Genfit is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Genfit has 1 study filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis, Biliary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06427395Phase 3Zydus Therapeutics Inc.Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | 2027-04-18 |
| NCT06825559Zydus Therapeutics Inc.Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | 2026-12-31 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07631442Stanford UniversityUsing Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC) | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
Drug: Placebo
Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
Drug: Elafibranor 80 mg
Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
Drug: Elafibranor 120 mg
Two coated tablets daily for 12 weeks
Also known as: GFT505
Two coated tablets daily for 12 weeks
Also known as: GFT505
Two coated tablets daily for 12 weeks
Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint)
Relative change from baseline is in serum ALP levels at Week 12 (endpoint) were reported. Relative change from baseline is defined as percentage (%) change from baseline to endpoint.
Time frame: Baseline, Week 12 (Endpoint)
Percentage of Participants With Response Defined by Composite Risk Scores (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] Within Normal Limits at Endpoint, and Greater Than [>] 15% ALP Reduction From Baseline to Endpoint)
Percentage of participants with response defined by Composite Risk Scores (ALP Less than \[\<\] 1.67 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 15% ALP reduction from baseline to Endpoint) was reported.
Time frame: Up to Week 12 (Endpoint)
Percentage of Participants With Response Defined by Composite Risk Scores (ALP < 2 * Upper Limit of Normal at Endpoint, Total Bilirubin Within Normal Limits at Endpoint, and > 40% ALP Reduction From Baseline to Endpoint)
Percentage of participants with response defined by composite risk scores (ALP \< 2 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 40% ALP reduction from baseline to endpoint) was reported.
Time frame: Up to Week 12 (Endpoint)
Percentage of Participants With Response Based on PARIS I Risk Score at Endpoint
Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (\<=) 3 \* ULN and aspartate aminotransferase (AST) \<= 2 \* ULN and bilirubin within normal limits.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Based on PARIS II Risk Score at Endpoint
Percentage of participants with response based on Paris II risk score was defined as ALP \<= 1.5 \* ULN and AST \<= 1.5 \* ULN and bilirubin within normal limits.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Based on Toronto I Risk Score at Endpoint
Percentage of participants with response based on Toronto I risk score was defined as ALP \<= 1.67 \*ULN.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Based on Toronto II Risk Score at Endpoint
Percentage of participants with response based on Toronto II risk scores was defined as ALP \<= 1.75 \* ULN.
Time frame: At Week 12 (Endpoint)
Median Percentage Risk as Assessed by United Kingdom-Primary Biliary Cholangitis (UK-PBC) Risk Total Score at Endpoint
UK-PBC risk score at endpoint estimated that the median percentage risk that a participant treated with ursodeoxycholic acid (UDCA) will develop liver failure requiring liver transplant in 5, 10 and 15 years. UK-PBC score was calculated at each of the 3 survivor functions 1-baseline survival function\^exp(0.0287854\*\[alpEPxuln-1.722136304\] - 0.0422873\*\[{(altastEPxuln/10)\^-1} - 8.675729006\] + 1.4199 \* \[ln{bilEPxuln /10}+2.709607778\] -1.960303\*\[albxlln -1.17673001\]-0.4161954\*\[ pltxlln -1.873564875\]). Where: Baseline survivor function=0. 982 (at 5 years); 0. 941 (at 10 years); 0.893 (at 15 years). alpEPxuln = ALP at endpoint/upper level normal ALP; altastEPxuln=(ALT, AST) at endpoint/upper level normal of the value; bilEPxuln=bilirubin at endpoint/upper level normal bilirubin; albxlln=albumin at baseline/albumin lower level normal; pltxlln=platelet count at baseline/ platelet count lower level normal.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Defined by 10, 20 and 40 Percent Reduction in Alkaline Phosphatase
Percentage of participants with response (defined by at least 10%, 20%, and 40% decrease in ALP from baseline to Endpoint) reported.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Endpoint
The response was defined by normalized ALP levels (ALP ULN 105 units per liter \[U/L\] for females, 129 U/L for males) at endpoint.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Defined by Normalized Bilirubin (BIL) at Endpoint
The response was defined by normalized BIL levels (BIL ULN \<1.20 milligram per deciliter \[mg/dL\]) at endpoint.
Time frame: At Week 12 (Endpoint)
Percentage of Participants With Response Defined by Normalized Albumin (ALB) Levels at Endpoint
The response was defined by normalized ALB levels (3.5-5.2 gram per deciliter \[g/dL\] for ages 18-60 years; 3.2-4.6 g/dL for ages 61-91 years) at endpoint.
Time frame: At Week 12 (Endpoint)
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Endpoint
Change from baseline in ALT levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Aspartate Aminotransferase (AST) Levels at Endpoint
Change from baseline in AST levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Gamma-glutamyl Transferase (GGT) Levels at Endpoint
Change from baseline in GGT levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in 5 Prime (') Nucleotidase Levels at Endpoint
Change from baseline in 5' nucleotidase levels at endpoint was reported. 5' nucleotidase is an enzyme used as a biomarker of hepatobiliary cholestasis and is less sensitive but more specific than GGT and ALP.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Total Bilirubin (BIL) Levels at Endpoint
Change from baseline in total BIL levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Conjugated Bilirubin Levels at Endpoint
Change from baseline in conjugated bilirubin levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Albumin Levels at Endpoint
Change from baseline in albumin levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Cholesterol Levels at Endpoint
Change from baseline in cholesterol levels at endpoints was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol Levels at Endpoint
Change from baseline in LDL-cholesterol at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in High-density Lipoprotein (HDL) Cholesterol Levels at Endpoint
Change from baseline in HDL-cholesterol levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Triglycerides Levels at Endpoint
Change from baseline in triglycerides levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Total Free Bile Acid Levels at Endpoint
Change from baseline in total free bile acid levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Total Conjugated Bile Acid Levels at Endpoint
Change from baseline in total conjugated bile acid levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Total Bile Acid Levels at Endpoint
Change from baseline in total bile acid levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in 7 Alpha-hydroxy-4-cholesten-3-one Levels at Endpoint
Change from baseline in 7 alpha-hydroxy-4-cholesten-3-one levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Fibroblast Growth Factor-19 Levels at Endpoint
Change from baseline in fibroblast growth factor-19 levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Immunoglobulin M (IgM) Levels at Endpoint
Change from baseline in IgM levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Tumor Necrosis Factor Levels at Endpoint
Change from baseline in tumor necrosis factor levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Transforming Growth Factor Beta Levels at Endpoint
Change from baseline in transforming growth factor beta levels at endpoint was reported,
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Interleukin 6 Levels at Endpoint
Change from baseline in interleukin 6 levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Plasminogen Activator Inhibitor-1 Antigen (AG) Levels at Endpoint
Change from baseline in plasminogen activator inhibitor-1 AG levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Cytokeratin-18 Levels at Endpoint
Change from baseline in cytokeratin-18 (M30 and M65) levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Autotaxin Levels at Endpoint
Change from baseline in autotaxin levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
C-reactive Protein Level at Endpoint
C-reactive protein level at endpoint was reported.
Time frame: Week 12 (Endpoint)
Change From Baseline in Haptoglobin Levels at Endpoint
Change from baseline in haptoglobin levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Fibrinogen Levels at Endpoint
Change from baseline in fibrinogen levels at endpoint was reported.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in 5D-Itch Scale Total Score
5 dimensional (5D)-Itch Scale is a reliable, multidimensional measure of itching that has been validated in participants with chronic pruritus to detect changes over time. It consists of 5 domains: duration, degree, direction, disability, and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items (sleep, leisure/social, housework/errands, work/school). All items of the first four domains were measured on a 5-point Likert scale. The distribution domain included 16 potential locations of itch, including 15 body part items (head/scalp, soles, face, palms, chest, abdomen, back, buttocks, thighs, lower legs, tops of feet/toes, tops of hands/fingers, upper arms, groin, forearms) and one point of contact with clothing or bandages. Scores of each of five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritus) and 25 (most severe pruritus).
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score
The VAS is a reliable and validated method of pruritus assessment. The VAS is adequate in assessing the severity of the symptom; it does not take into account other aspects of pruritus, such as the relative impact of pruritus on quality of life. The VAS, for pruritus assessment, requires the participant to use abstract thought processes to convert their itch severity to a mark on a continuum. A participant draws a line anywhere on the scale ranging from 0 to 10 (where 0 represents 'no itching' and 10 represents 'worst possible itching') that best represents the severity of participant's itching and the scoring involves manual measuring of the mark with a ruler on range of 0 to 100 millimeter (mm). Higher scores indicate worse itching.
Time frame: Baseline, Week 12 (Endpoint)
Change From Baseline in Primary Biliary Cholangitis -40 (PBC-40) Quality of Life (QoL) Questionnaire Scores
PBC-40 QoL Questionnaire is a patient-derived, disease-specific QoL measure developed and validated for use in PBC. It consists of 9 domains with total 40 questions as: 1) digestion and diet (questions 1-3, total score range: 3-15); 2) experiences (questions 4-7, total score range: 4-20); 3) itching (questions 8-10, total score range: 3-15); 4) fatigue (questions 11-18, total score range: 8-40); 5) effort and planning (questions 19-21, total score range: 3-15); 6) memory and concentration (questions 22-27, total score range: 6-30); 7) affects you as a person (questions 28-33, total score range: 6-30); 8) affects your social life (questions 34-37, total score range: 4-20); 9) overall impact on your life (questions 38-40, total score range: 3-15). PBC-40 QoL Questionnaire has 40 questions, each scored on scale of 1-5 (1 = least impact, 5 = greatest impact). For each domain, scoring involved summing individual question response scores. Higher scores indicate poorer quality of life.
Time frame: Baseline, Week 12 (Endpoint)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Treatment Emergent Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization/prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is another medically important condition. TEAEs is defined as (1) it is not present when active phase of study (time of first dose) begins and is not a chronic condition that is part of patient's medical history, or it is present at start of active phase or as part of patient's medical history, but severity/frequency increases during active phase.
Time frame: Up to Week 12
| Milestone | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Started | 15 | 15 | 15 |
| Completed | 15 | 14 | 15 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
Relative change from baseline is in serum ALP levels at Week 12 (endpoint) were reported. Relative change from baseline is defined as percentage (%) change from baseline to endpoint.
| Percent change | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) Levels at Week 12 (Endpoint) | -48.264 ± 14.7676 | -40.640 ± 17.3624 | 3.190 ± 14.8059 |
Percentage of participants with response defined by Composite Risk Scores (ALP Less than \[\<\] 1.67 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 15% ALP reduction from baseline to Endpoint) was reported.
| Percentage of participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Defined by Composite Risk Scores (ALP< 1.67 * Upper Limit of Normal [ULN] at Endpoint, Total Bilirubin [BIL] Within Normal Limits at Endpoint, and Greater Than [>] 15% ALP Reduction From Baseline to Endpoint) | 66.7 | 78.6 | 6.7 |
Percentage of participants with response defined by composite risk scores (ALP \< 2 \* ULN at endpoint, Total BIL within normal limits at endpoint, and \> 40% ALP reduction from baseline to endpoint) was reported.
| Percentage of participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Defined by Composite Risk Scores (ALP < 2 * Upper Limit of Normal at Endpoint, Total Bilirubin Within Normal Limits at Endpoint, and > 40% ALP Reduction From Baseline to Endpoint) | 73.3 | 42.9 | 0 |
Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (\<=) 3 \* ULN and aspartate aminotransferase (AST) \<= 2 \* ULN and bilirubin within normal limits.
| Percentage of participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Based on PARIS I Risk Score at Endpoint | 80.0 | 78.6 | 53.3 |
Percentage of participants with response based on Paris II risk score was defined as ALP \<= 1.5 \* ULN and AST \<= 1.5 \* ULN and bilirubin within normal limits.
| Percentage of participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Based on PARIS II Risk Score at Endpoint | 53.3 | 50.0 | 0 |
Percentage of participants with response based on Toronto I risk score was defined as ALP \<= 1.67 \*ULN.
| Percentage of participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Based on Toronto I Risk Score at Endpoint | 66.7 | 78.6 | 6.7 |
Percentage of participants with response based on Toronto II risk scores was defined as ALP \<= 1.75 \* ULN.
| Percentage of participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Based on Toronto II Risk Score at Endpoint | 66.7 | 78.6 | 6.7 |
UK-PBC risk score at endpoint estimated that the median percentage risk that a participant treated with ursodeoxycholic acid (UDCA) will develop liver failure requiring liver transplant in 5, 10 and 15 years. UK-PBC score was calculated at each of the 3 survivor functions 1-baseline survival function\^exp(0.0287854\*\[alpEPxuln-1.722136304\] - 0.0422873\*\[{(altastEPxuln/10)\^-1} - 8.675729006\] + 1.4199 \* \[ln{bilEPxuln /10}+2.709607778\] -1.960303\*\[albxlln -1.17673001\]-0.4161954\*\[ pltxlln -1.873564875\]). Where: Baseline survivor function=0. 982 (at 5 years); 0. 941 (at 10 years); 0.893 (at 15 years). alpEPxuln = ALP at endpoint/upper level normal ALP; altastEPxuln=(ALT, AST) at endpoint/upper level normal of the value; bilEPxuln=bilirubin at endpoint/upper level normal bilirubin; albxlln=albumin at baseline/albumin lower level normal; pltxlln=platelet count at baseline/ platelet count lower level normal.
| Percentage risk | Elafibranor 80mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| 5 year risk at Week 12 | 0.80 (0.1 to 6.0) | 0.95 (0.2 to 5.8) | 1.30 (0.1 to 3.7) |
| 10 year risk at Week 12 | 2.60 (0.3 to 18.8) | 3.05 (0.8 to 18.1) | 4.40 (0.5 to 12.0) |
| 15 year risk at Week 12 | 4.70 (0.6 to 32.1) | 5.55 (1.5 to 31.0) | 8.00 (0.9 to 21.1) |
Percentage of participants with response (defined by at least 10%, 20%, and 40% decrease in ALP from baseline to Endpoint) reported.
| Percentage of participants | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| 10 Percent Reduction | 93.3 | 92.9 | 13.3 |
| 20 Percent Reduction | 93.3 | 92.9 | 6.7 |
| 40 Percent Reduction | 86.7 | 57.1 | 0 |
The response was defined by normalized ALP levels (ALP ULN 105 units per liter \[U/L\] for females, 129 U/L for males) at endpoint.
| Percentage of participants | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Endpoint | 13.3 | 21.4 | 0 |
The response was defined by normalized BIL levels (BIL ULN \<1.20 milligram per deciliter \[mg/dL\]) at endpoint.
| Percentage of participants | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Defined by Normalized Bilirubin (BIL) at Endpoint | 86.7 | 92.9 | 93.3 |
The response was defined by normalized ALB levels (3.5-5.2 gram per deciliter \[g/dL\] for ages 18-60 years; 3.2-4.6 g/dL for ages 61-91 years) at endpoint.
| Percentage of participants | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response Defined by Normalized Albumin (ALB) Levels at Endpoint | 100 | 100 | 100 |
Change from baseline in ALT levels at endpoint was reported.
| U/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Alanine Aminotransferase (ALT) Levels at Endpoint | -0.5 ± 57.38 | 7.3 ± 29.13 | -1.2 ± 8.57 |
Change from baseline in AST levels at endpoint was reported.
| U/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Aspartate Aminotransferase (AST) Levels at Endpoint | 6.0 ± 55.29 | 11.1 ± 27.96 | -4.3 ± 7.97 |
Change from baseline in GGT levels at endpoint was reported.
| U/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Gamma-glutamyl Transferase (GGT) Levels at Endpoint | -91.5 ± 95.30 | -61.9 ± 70.82 | 0.6 ± 54.40 |
Change from baseline in 5' nucleotidase levels at endpoint was reported. 5' nucleotidase is an enzyme used as a biomarker of hepatobiliary cholestasis and is less sensitive but more specific than GGT and ALP.
| U/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 5 Prime (') Nucleotidase Levels at Endpoint | -7.81 ± 8.279 | -4.59 ± 13.067 | -0.47 ± 3.491 |
Change from baseline in total BIL levels at endpoint was reported.
| micromole per liter (mcmol/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Bilirubin (BIL) Levels at Endpoint | -0.23 ± 3.425 | -0.51 ± 2.821 | -0.01 ± 3.548 |
Change from baseline in conjugated bilirubin levels at endpoint was reported.
| mcmol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Conjugated Bilirubin Levels at Endpoint | 0.34 ± 2.229 | -0.06 ± 0.596 | 0.45 ± 1.526 |
Change from baseline in albumin levels at endpoint was reported.
| gram per liter (g/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Albumin Levels at Endpoint | 2.2 ± 2.54 | 2.3 ± 2.73 | 0.0 ± 2.20 |
Change from baseline in cholesterol levels at endpoints was reported.
| millimole per liter (mmol/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Cholesterol Levels at Endpoint | -0.455 ± 0.7479 | -0.387 ± 0.6308 | 0.043 ± 0.3706 |
Change from baseline in LDL-cholesterol at endpoint was reported.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Low-density Lipoprotein (LDL) Cholesterol Levels at Endpoint | -0.366 ± 0.5919 | -0.334 ± 0.4848 | 0.061 ± 0.3272 |
Change from baseline in HDL-cholesterol levels at endpoint was reported.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in High-density Lipoprotein (HDL) Cholesterol Levels at Endpoint | -0.017 ± 0.3898 | 0.059 ± 0.3391 | -0.007 ± 0.2988 |
Change from baseline in triglycerides levels at endpoint was reported.
| mmol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Triglycerides Levels at Endpoint | -0.155 ± 0.3460 | -0.253 ± 0.2085 | -0.019 ± 0.3776 |
Change from baseline in total free bile acid levels at endpoint was reported.
| 10^-9 mole per liter (mol/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Free Bile Acid Levels at Endpoint | -248.88 ± 2496.672 | -673.71 ± 2962.097 | -135.20 ± 6777.727 |
Change from baseline in total conjugated bile acid levels at endpoint was reported.
| 10^-9 mol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Conjugated Bile Acid Levels at Endpoint | 5008.99 ± 17844.304 | -3280.16 ± 10941.769 | 1873.22 ± 21795.349 |
Change from baseline in total bile acid levels at endpoint was reported.
| 10^-9 mol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Bile Acid Levels at Endpoint | 4760.11 ± 18919.661 | -3953.86 ± 12008.620 | 1738.02 ± 26521.746 |
Change from baseline in 7 alpha-hydroxy-4-cholesten-3-one levels at endpoint was reported.
| 10^-9 mol/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 7 Alpha-hydroxy-4-cholesten-3-one Levels at Endpoint | -16.29 ± 27.584 | -10.04 ± 28.606 | 5.22 ± 10.848 |
Change from baseline in fibroblast growth factor-19 levels at endpoint was reported.
| nanogram per liter (ng/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fibroblast Growth Factor-19 Levels at Endpoint | -21.67 ± 52.588 | -16.96 ± 38.933 | -47.08 ± 69.560 |
Change from baseline in IgM levels at endpoint was reported.
| g/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Immunoglobulin M (IgM) Levels at Endpoint | -0.339 ± 0.5846 | -0.472 ± 0.5507 | -0.076 ± 0.7227 |
Change from baseline in tumor necrosis factor levels at endpoint was reported.
| ng/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Tumor Necrosis Factor Levels at Endpoint | 0.066 ± 0.7829 | 0.154 ± 1.1374 | 0.053 ± 0.8329 |
Change from baseline in transforming growth factor beta levels at endpoint was reported,
| ng/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Transforming Growth Factor Beta Levels at Endpoint | 734.7 ± 2103.75 | 297.2 ± 2762.61 | -1163.0 ± 4295.49 |
Change from baseline in interleukin 6 levels at endpoint was reported.
| ng/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Interleukin 6 Levels at Endpoint | -0.021 ± 0.8337 | -0.261 ± 0.5213 | -0.165 ± 0.5624 |
Change from baseline in plasminogen activator inhibitor-1 AG levels at endpoint was reported.
| microgram per liter (mcg/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Plasminogen Activator Inhibitor-1 Antigen (AG) Levels at Endpoint | -0.483 ± 2.9839 | -1.739 ± 4.6587 | -1.456 ± 4.6448 |
Change from baseline in cytokeratin-18 (M30 and M65) levels at endpoint was reported.
| picomole per liter (pmol/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Cytokeratin-18 M30 | 26.12 ± 472.247 | 163.33 ± 499.500 | 17.93 ± 307.531 |
| Cytokeratin-18 M65 | 114.31 ± 627.068 | 238.97 ± 611.520 | -53.16 ± 131.934 |
Change from baseline in autotaxin levels at endpoint was reported.
| mcg/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Autotaxin Levels at Endpoint | 4.6 ± 156.92 | 49.9 ± 77.25 | 35.1 ± 161.58 |
C-reactive protein level at endpoint was reported.
| milligram per liter (mg/L) | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| C-reactive Protein Level at Endpoint | 2.74 (1.81 to 4.14) | 2.84 (1.68 to 4.78) | 4.01 (2.52 to 6.37) |
Change from baseline in haptoglobin levels at endpoint was reported.
| g/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Haptoglobin Levels at Endpoint | -0.265 ± 0.4271 | -0.254 ± 0.1088 | 0.025 ± 0.2244 |
Change from baseline in fibrinogen levels at endpoint was reported.
| g/L | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fibrinogen Levels at Endpoint | -0.865 ± 0.9472 | -0.452 ± 0.5780 | -0.072 ± 1.0936 |
5 dimensional (5D)-Itch Scale is a reliable, multidimensional measure of itching that has been validated in participants with chronic pruritus to detect changes over time. It consists of 5 domains: duration, degree, direction, disability, and distribution. The duration, degree and direction domains each include one item, while the disability domain has four items (sleep, leisure/social, housework/errands, work/school). All items of the first four domains were measured on a 5-point Likert scale. The distribution domain included 16 potential locations of itch, including 15 body part items (head/scalp, soles, face, palms, chest, abdomen, back, buttocks, thighs, lower legs, tops of feet/toes, tops of hands/fingers, upper arms, groin, forearms) and one point of contact with clothing or bandages. Scores of each of five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritus) and 25 (most severe pruritus).
| Units on a scale | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 5D-Itch Scale Total Score | -2.1 ± 5.15 | -0.1 ± 2.19 | 0.8 ± 4.93 |
The VAS is a reliable and validated method of pruritus assessment. The VAS is adequate in assessing the severity of the symptom; it does not take into account other aspects of pruritus, such as the relative impact of pruritus on quality of life. The VAS, for pruritus assessment, requires the participant to use abstract thought processes to convert their itch severity to a mark on a continuum. A participant draws a line anywhere on the scale ranging from 0 to 10 (where 0 represents 'no itching' and 10 represents 'worst possible itching') that best represents the severity of participant's itching and the scoring involves manual measuring of the mark with a ruler on range of 0 to 100 millimeter (mm). Higher scores indicate worse itching.
| Units on a scale | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Pruritus as Assessed by Visual Analogue Scale (VAS) Total Score | -4.4 ± 22.80 | -4.7 ± 11.81 | 9.3 ± 35.93 |
PBC-40 QoL Questionnaire is a patient-derived, disease-specific QoL measure developed and validated for use in PBC. It consists of 9 domains with total 40 questions as: 1) digestion and diet (questions 1-3, total score range: 3-15); 2) experiences (questions 4-7, total score range: 4-20); 3) itching (questions 8-10, total score range: 3-15); 4) fatigue (questions 11-18, total score range: 8-40); 5) effort and planning (questions 19-21, total score range: 3-15); 6) memory and concentration (questions 22-27, total score range: 6-30); 7) affects you as a person (questions 28-33, total score range: 6-30); 8) affects your social life (questions 34-37, total score range: 4-20); 9) overall impact on your life (questions 38-40, total score range: 3-15). PBC-40 QoL Questionnaire has 40 questions, each scored on scale of 1-5 (1 = least impact, 5 = greatest impact). For each domain, scoring involved summing individual question response scores. Higher scores indicate poorer quality of life.
| Units on a scale | Elafibranor 80 mg | Elafibranor 120 mg | Placebo |
|---|---|---|---|
| Digestion and Diet | -0.3 ± 2.74 | -0.6 ± 2.24 | -0.6 ± 3.00 |
| Experiences | 0.6 ± 2.64 | -1.3 ± 1.77 | -0.7 ± 3.69 |
| Itching | -0.9 ± 6.19 | -4.1 ± 6.56 | 2.1 ± 5.78 |
| Fatigue | -1.9 ± 4.10 | -1.4 ± 2.71 | -1.5 ± 5.04 |
| Effort and Planning | -0.9 ± 2.03 | -0.8 ± 1.31 | -0.9 ± 1.98 |
| Memory and concentration | 0.1 ± 3.26 | -1.5 ± 3.33 | -0.5 ± 3.25 |
| Affecting you as a Person | -1.8 ± 3.78 | -2.5 ± 2.85 | -1.3 ± 3.22 |
| Affects your Social Life | 1.3 ± 3.08 | 0.0 ± 1.47 | 1.4 ± 4.79 |
| Impact on your Life | -0.1 ± 3.04 | 0.6 ± 0.63 | -1.0 ± 3.30 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization/prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is another medically important condition. TEAEs is defined as (1) it is not present when active phase of study (time of first dose) begins and is not a chronic condition that is part of patient's medical history, or it is present at start of active phase or as part of patient's medical history, but severity/frequency increases during active phase.
| Participants | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| TEAEs | 12 | 13 | 12 |
| Serious TEAEs | 0 | 2 | 0 |
Collected over Up to 16 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elafibranor 80mg | 13/15 (86.7%) | 0/15 (0%) | 12/15 (80%) |
| Elafibranor 120mg | 13/15 (86.7%) | 2/15 (13.3%) | 13/15 (86.7%) |
| Placebo | 12/15 (80%) | 0/15 (0%) | 12/15 (80%) |
| Event | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| Autoimmune HepatitisHepatobiliary disorders | 0/15 | 1/15 | 0/15 |
| Post Procedural StrokeInjury, poisoning and procedural complications | 0/15 | 1/15 | 0/15 |
| Ischaemic StrokeNervous system disorders | 0/15 | 1/15 | 0/15 |
| Event | Elafibranor 80mg | Elafibranor 120mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 0/15 | 3/15 | 1/15 |
| FatigueGeneral disorders | 1/15 | 3/15 | 0/15 |
| Urinary Tract InfectionInfections and infestations | 1/15 | 3/15 | 0/15 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 3/15 | 0/15 | 2/15 |
| PruritusSkin and subcutaneous tissue disorders | 3/15 | 3/15 | 2/15 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 2/15 | 2/15 |
| DizzinessNervous system disorders | 2/15 | 0/15 | 1/15 |
| HeadacheNervous system disorders | 2/15 | 2/15 | 1/15 |
| VertigoEar and labyrinth disorders | 1/15 | 0/15 | 0/15 |
| Dry EyeEye disorders | 0/15 | 1/15 | 0/15 |
| Age, Categorical(Participants) | Elafibranor 80mg | Elafibranor 120mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 10 | 11 | 34 |
| >=65 years | 2 | 5 | 4 | 11 |
| Age, Continuous(Years) | Elafibranor 80mg | Elafibranor 120mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 56.5 ± 8.7 | 60.4 ± 6.9 | 60.5 ± 8.6 | 59.1 ± 8.2 |
| Sex: Female, Male(Participants) | Elafibranor 80mg | Elafibranor 120mg | Placebo | Total |
|---|---|---|---|---|
| Female | 14 | 15 | 14 | 43 |
| Male | 1 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Elafibranor 80mg | Elafibranor 120mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 | 10 |
| Not Hispanic or Latino | 12 | 13 | 10 | 35 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Elafibranor 80mg | Elafibranor 120mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 15 | 15 | 14 | 44 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Oct 2018, 18 months.
Results were first posted in Sep 2019, 10 months after primary completion.
Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elifibranor